G
Greenwich LifeSciences, Inc. (GLSI)
NCM – Real vaqt narxi. Valyuta: USD
24.71
+0.58 (2.40%)
Yopilishda: May 12, 2026, 4:00 PM EDT
24.26
-0.45 (-1.82%)
Bozor oldidan: May 13, 2026, 5:24 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
24.71
+0.58 (2.40%)
Yopilishda: May 12, 2026, 4:00 PM EDT
24.26
-0.45 (-1.82%)
Bozor oldidan: May 13, 2026, 5:24 AM EDT
Greenwich LifeSciences, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlar va Ruminiyada ko'krak bezi rakini va HER2/neu-ifodalovchi boshqa saratonlarni davolash uchun yangi rak immunoterapiyalarini ishlab chiqadi. Uning asosiy mahsulot nomzodi GP2 bo'lib, bu immunoterapiya bo'lib, u ilgari operatsiya qilingan bemorlarda ko'krak bezi rakining qaytalanishini oldini olish uchun III bosqich klinik sinovlarida. Kompaniya, shuningdek, HER2-musbat ko'krak bezi rakiga chalingan bemorlarda GLSI-100 (GP2 + GM-CSF) ning xavfsizligi va samaradorligini baholash uchun ishlab chiqilgan III bosqich klinik sinovlarida bo'lgan FLAMINGO-01 ni ishlab chiqmoqda. Greenwich LifeSciences, Inc. ilgari Norwell, Inc. nomi bilan tanilgan va 2018 yil mart oyida Greenwich LifeSciences, Inc. nomini o'zgartirgan. Kompaniya 2006 yilda tashkil etilgan va Stafford, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christine T. Fischette Ph.D. | VP of Business Development |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs |
| Mr. Eric Rothe | Founder & Independent Director |
| Mr. Snehal S. Patel | CEO, CFO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-31 | NT 10-K | formnt10-k.htm |
| 2025-12-18 | 8-K | form8-k.htm |
| 2025-11-14 | 10-Q | form10-q.htm |
| 2025-11-03 | DEFA14A | formdefa14a.htm |
| 2025-11-03 | ARS | formars.pdf |
| 2025-08-14 | 10-Q | form10-q.htm |
| 2025-07-24 | 8-K | form8-k.htm |
| 2025-05-20 | 10-Q | form10-q.htm |
| 2025-04-15 | 10-K | form10-k.htm |
| 2025-03-31 | NT 10-K | formnt10-k.htm |